Gilead Sciences, Inc.
NASDAQGilead Sciences has now printed its Q2 results and the immediate market reaction tells a cleaner story than the analyst community does — the stock jumped 3.1% on August 4 to $135.25, erasing the hesitation that had built into the print. The post-earnings price action diverges sharply from the last comparable event. May's Q1 release sent the stock down 3.6% on the day and a further…
Snapshot as of 6 Aug 2026
A new long-form analysis for GILD this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumGilead Sciences has now printed its Q2 results and the immediate market reaction tells a cleaner story than the analyst community does — the stock jumped 3.1% on August 4 to $135.25, erasing the hesitation that had…
Gilead Sciences reports Q3 results on August 7 having already absorbed one quarterly print — a May release that sent the stock down 3.6% on the day and a further 3.1% over the following week — yet the stock has…
Gilead Sciences reports Q2 results today after the bell with the bullish options fervor from last week fading and the analyst community in a distinctly cautious mood. The options picture has shifted since the prior…
Gilead Sciences heads into its August 4 Q2 print with options traders at their most bullish in a year and the Street sending conflicting signals on valuation. The clearest read this week is in the options market. The…
Gilead Sciences heads into the back half of summer with a notable catalyst in the rearview mirror — a bellwether upgrade that broke a run of analyst caution and helped push the stock to its best weekly gain in…
Gilead Sciences heads into the back half of May nursing a 3.3% weekly decline and a 5.2% one-month loss — a drift that an upgrade this morning from Maxim Group has not been enough to arrest. The freshest piece of…
Gilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April. The…
Gilead Sciences walks into its Q1 2026 results — scheduled for after the close on April 30 — with a notable tension: short interest has risen sharply over the past month, yet the Street remains firmly bullish and a…
Short sellers have largely abandoned GILD ahead of today's earnings. Just 1.73% of the float is sold short, up slightly from March lows but still among the lowest in large-cap biotech. Short interest stands at 21.5…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GILD — free to start on ORTEX.
Sign up for free →Open GILD on ORTEX